Permira, the global private equity firm, today announced that a company backed by the Permira funds has agreed to acquire Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS) from funds advised by Apax Partners.
OnKure, a leader in discovery and development of next generation histone deacetylase (HDAC) inhibitors, entered into a clinical trial collaboration and supply agreement with Pfizer to support the clinical proof of concept study for MEKTOVI (binimetinib) in combination with OKI-179, a highly potent and tolerable Class I HDAC inhibitor currently in Phase I for the treatment of NRAS melanoma.
Swiss drugmaker Roche has completed a share purchase agreement to acquire an Irish biotechnology company Inflazome for an upfront payment of €380m.
AstraZeneca has acquired a preclinical oral PCSK9 inhibitor programme from Dogma Therapeutics for an undisclosed price.
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), announced a collaboration aimed at the discovery and development of mRNA therapeutics for the treatment of pulmonary arterial hypertension (PAH), a rare disease with an incidence of 2-5 per million adults.
Takeda Pharmaceutical has opened a new 24,000ft² research and development (R&D) therapy manufacturing facility in Massachusetts, US.
HiFiBiO Therapeutics has entered into a partnership with South Korea-based ABL Bio to co-develop its SARS-CoV-2 neutralising antibody HFB30132A for the treatment of Covid-19.
Drug-maker Merck has announced the acquisition of a $1bn equity stake in biotechnology company Seattle Genetics.
Gilead Sciences has agreed to acquire Immunomedics, a US biopharma company engaged in the development of antibody-drug conjugates (ADCs) for cancer, in a deal worth around $21bn.
Exelixis and NBE-Therapeutics announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific conjugation and novel payloads.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.